Obiltoxaximab information

Obiltoxaximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	Bacillus anthracis anthrax
Clinical data
Trade names	Anthim, Nyxthracis, others
Other names	ETI-204
AHFS/Drugs.com	Monograph
License data	US DailyMed: Obiltoxaximab;
Routes of; administration	Intravenous
ATC code	J06BC04 (WHO) ;
Legal status
Legal status	CA: ℞-only / Schedule D; US: WARNINGRx-only; EU: Rx-only;
Identifiers
CAS Number	1351337-07-9;
DrugBank	DB05336;
ChemSpider	None;
UNII	29Z5DNL48C;
KEGG	D10776 ;
Chemical and physical data
Formula	C6444H9994N1734O2022S44
Molar mass	145521.59 g·mol−1

Obiltoxaximab, sold under the brand name Anthim among others, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).^[6]^[3]^[7]

The medication was developed by Elusys Therapeutics, Inc.^[3]^[8]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Summary Basis of Decision (SBD) for Anthim". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ ^a ^b ^c "Anthim- obiltoxaximab solution". DailyMed. 9 December 2019. Retrieved 21 September 2020.
^ Cite error: The named reference Nyxthracis EPAR was invoked but never defined (see the help page).
^ "Nyxthracis Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.
^ Hou AW, Morrill AM (October 2017). "Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection". The Annals of Pharmacotherapy. 51 (10): 908–913. doi:10.1177/1060028017713029. PMID 28573869. S2CID 39810240.
^
"Anthim (obiltoxaximab) Injection". U.S. Food and Drug Administration (FDA). 26 April 2016. Retrieved 18 October 2020.
- "Center for Drug Evaluation and Research: Application Number: 125509Orig1s000: Summary Review" (PDF). Food and Drug Administration.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[2] "Summary Basis of Decision (SBD) for Anthim". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[Anthim_FDA_label-3] "Anthim- obiltoxaximab solution". DailyMed. 9 December 2019. Retrieved 21 September 2020.

[Nyxthracis_EPAR-4] Cite error: The named reference Nyxthracis EPAR was invoked but never defined (see the help page).

[5] "Nyxthracis Product information". Union Register of medicinal products. Retrieved 3 March 2023.

[6] Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.

[Hou_2017-7] Hou AW, Morrill AM (October 2017). "Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection". The Annals of Pharmacotherapy. 51 (10): 908–913. doi:10.1177/1060028017713029. PMID 28573869. S2CID 39810240.

[8] "Anthim (obiltoxaximab) Injection". U.S. Food and Drug Administration (FDA). 26 April 2016. Retrieved 18 October 2020.
"Center for Drug Evaluation and Research: Application Number: 125509Orig1s000: Summary Review" (PDF). Food and Drug Administration.

[9] "Center for Drug Evaluation and Research: Application Number: 125509Orig1s000: Summary Review" (PDF). Food and Drug Administration.

Obiltoxaximab information

and 9 Related for: Obiltoxaximab information

Obiltoxaximab

ATC code J06

Anthrax

Anthim

Monoclonal antibody therapy

ZMapp

Jennifer Maynard

Antibody Solutions

Anthrax vaccine adsorbed